image: A full house for the opening presentation of day two of the SNMMI Therapeutics Conference.
Credit: Images courtesy of SNMMI.
Reston, VA (September 23, 2024)—More than 300 nuclear medicine clinicians, researchers, technologists, regulators and suppliers gathered in Bethesda, Maryland, on September 19-21, for the Society of Nuclear Medicine and Molecular Imaging (SNMMI) 2024 Therapeutics Conference. As the largest SNMMI Therapeutics Conference to date, the meeting offered attendees the chance to explore the latest innovations and advancements in theranostics and other nuclear medicine therapies as well as gain valuable insights into enhancing their practice.
This year’s Therapeutics Conference included eight distinct sessions covering advances in radiopharmaceutical therapies. Several sessions focused on disease-specific therapies, including pediatric therapies, prostate cancer, thyroid diseases, and neuroendocrine tumors, while others addressed issues related to dosimetry, access, supply chain, clinical trials, and research. The conference also included a pre-meeting workshop on streamlining collaborations for study start-ups, a dosimetry hands-on open house, and multiple industry satellite symposia.
“There is so much excitement surrounding theranostics and nuclear medicine therapy, and the SNMMI Therapeutics Conference provided the perfect platform for key players in the field to share and learn from each other,” said Cathy Sue Cutler, PhD, FSNMMI, president of SNMMI.
The conference was organized and moderated by Phillip Koo, MD, Banner MD Anderson Cancer Center, and Hossein Jadvar, MD, PhD, University of Southern California. Attendees appreciated the participation of 34 radiopharmaceutical therapy companies in the exhibit hall, offering attendees the chance to converse directly with industry professionals.
“SNMMI has fostered nuclear medicine therapies and theranostics since the society was founded in 1953,” said Cutler. “From education to clinical trials to standards and guidelines, SNMMI aims to provide nuclear medicine and other medical professionals with the resources necessary to advance theranostics and improve patient care.”
The 2025 SNMMI Therapeutics Conference will be held in Fall 2025. For more information on SNMMI’s resources and activities to support theranostics, visit www.snmmi.org/therapy.
###
About the Society of Nuclear Medicine and Molecular Imaging
The Society of Nuclear Medicine and Molecular Imaging (SNMMI) is an international scientific and medical organization dedicated to advancing nuclear medicine, molecular imaging and theranostics—vital elements of precision medicine that allow diagnosis and treatment to be tailored to individual patients in order to achieve the best possible outcomes.
SNMMI’s members set the standard for molecular imaging and nuclear medicine practice by creating guidelines, sharing information through journals and meetings and leading advocacy on key issues that affect nuclear medicine research and practice. For more information, visit www.snmmi.org.